Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 2/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232368 | 1.00 | RAD51 (0.54) | RAD51CYP11B1CYP11B2PIK3CDPIK3CA | |
| SCHEMBL122510 | 0.80 | RAD51 (0.53) | RAD51PIK3CDPIK3CAPIK3CBTRPV4 | |
| SCHEMBL170120 | 0.75 | RAD51 (0.37) | RAD51CYP11B1CYP11B2P4HBAPP | |
| SCHEMBL2464723 | 0.75 | ALDH1A1 (0.43) | RAD51CYP11B1CYP11B2APPCASP3 | |
| SCHEMBL2886893 | 0.75 | ALDH1A1 (0.43) | RAD51CYP11B1CYP11B2APPCASP3 | |
| SCHEMBL395034 | 0.74 | RAD51 (0.36) | RAD51APP | |
| SCHEMBL395035 | 0.74 | RAD51 (0.36) | RAD51APP | |
| SCHEMBL12653177 | 0.73 | AR (0.43) | RAD51APP | |
| SCHEMBL1799897 | 0.72 | VCAM1 (0.51) | RAD51PTGS2 | |
| SCHEMBL6614751 | 0.72 | VCAM1 (0.51) | RAD51PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-18 | — | — | US | disclosed |
| US-11337973-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | US | disclosed |
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-19 | — | — | US | disclosed |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20200375986-A1 | SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200339567-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | US | disclosed |
| US-10722501-B2 | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-28 | — | — | US | disclosed |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110028479-A1 | SUBSTITUTED PYRROLOTRIAZINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-02-03 | — | — | US | disclosed |
| CN-101903356-A | 4- (4-cyano-2-thioaryl) dihydropyrimidinones and their use | BAYER HEALTHCARE AG | 2010-12-01 | — | — | CN | disclosed |
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| EP-2234985-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010078953-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
| US-20100010024-A1 | USE OF1,4-DIARYL-DIHYDROPYRIMIDINE-2-ON DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2009135599-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375986-A1 | SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME | PREP, SERPINB1, PEPD | RAD51 4586/4885CYP11B1 854/4885CYP11B2 537/4885 |
| US-11337973-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors | PREP, PEPD, SERPINB1 | RAD51 4748/4885CYP11B1 728/4885CYP11B2 608/4885 |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, ARG2, GOT2 | RAD51 4049/4885CYP11B1 1174/4885CYP11B2 356/4885 |
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | AADAC, ARG2, GOT2 | RAD51 4049/4885CYP11B1 1174/4885CYP11B2 356/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | RAD51 4002/4885CYP11B1 906/4885CYP11B2 295/4885 |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | HMGCR, PCSK9, FABP3 | RAD51 2426/4885CYP11B1 16/4885CYP11B2 11/4885 |
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMS | RAD51 1590/4885CYP11B1 206/4885CYP11B2 130/4885 |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | RAD51 4671/4885CYP11B1 246/4885CYP11B2 181/4885 |
| US-10722501-B2 | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof | PTGIS, CYP11B2, IL1B | RAD51 3353/4885CYP11B1 9/4885CYP11B2 2/4885 |
| US-20110028479-A1 | SUBSTITUTED PYRROLOTRIAZINES AND THEIR USE | PTGIR, PTGIS, PTGER2 | RAD51 3860/4885CYP11B1 112/4885CYP11B2 49/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | RAD51 4671/4885CYP11B1 246/4885CYP11B2 181/4885 |
| US-20200339567-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | GOT2, ABAT, OAT | RAD51 3772/4885CYP11B1 32/4885CYP11B2 18/4885 |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | RAD51 4553/4885CYP11B1 18/4885CYP11B2 8/4885 |
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | RAD51 4671/4885CYP11B1 246/4885CYP11B2 181/4885 |
| US-20100010024-A1 | USE OF1,4-DIARYL-DIHYDROPYRIMIDINE-2-ON DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTENSION | PTGS1, DPYD, PTGIS | RAD51 1715/4885CYP11B1 47/4885CYP11B2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.